Psoriatic Arthritis
Conditions
Keywords
Methotrexate, Efficacy, Safety
Brief summary
A Phase 2, Multicenter, Open-Label Extension (OLE) Study with ABT-122 in Active Psoriatic Arthritis Subjects Who Have Completed a Preceding Study M14-197 Phase 2 Randomized Controlled Trial (RCT).
Interventions
DRUGABT-122
Injection
Sponsors
AbbVie
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
1. Subjects who have completed preceding Study M14-197 (ABT-122) RCT study and have not developed any discontinuation criteria of Study M14-197. 2. If female, subject must meet one of the following criteria: * Postmenopausal (defined as no menses for at least 1 year). * Surgically sterile (bilateral oophorectomy or hysterectomy) If subject does not meet one of the above two categories, subject must use one of the following methods of birth control, from the time of the first dose of study drug until 150 days after the last dose of study drug: * Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation started at least 2 months prior to the first dose of study drug: oral, intravaginal or transdermal * Progestogen-only hormonal contraception associated with inhibition of ovulation started at least two months prior to randomization: oral, injectable, or implantable * Intrauterine device (IUD) * Intrauterine hormone-releasing system (IUS) * Bilateral tubal occlusion/ligation * Be with a vasectomized partner (procedure at least 6 months earlier, the vasectomized male partner should be your sole partner) * Sexual abstinence (refraining from heterosexual intercourse during the entire study period) 3. If male, subject must be surgically sterile (have had a vasectomy more than 6 months prior to Screening) or must be practicing at least 1 of the following methods of birth control from the time of the first dose of study drug until 150 days post last dose of study drug: * Subject using condom and female partner(s) using an intrauterine device (IUD); * Subject using condom and female partner(s) using hormonal contraceptives (oral, vaginal, parenteral or transdermal); * Subject using condom and female partner(s) using double-barrier method (contraceptive sponge; diaphragm or vaginal ring with spermicidal jellies, creams, or spermicide); * Total abstinence from sexual intercourse as the preferred lifestyle of the subject; periodic abstinence is not acceptable. * Subject must also agree to not donate sperm starting on the first day of study drug administration until 150 days after the last dose of study drug. 4. Subjects must voluntarily sign and date an informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any study-specific procedures. 5. Subject is judged to be in good health as determined by the Investigator.
Exclusion criteria
1. Pregnant or breastfeeding or plans to become pregnant during study participation. 2. Ongoing infections at Day 1 (Week 0) that have NOT been successfully treated within 14 days. 3. Anticipated requirement or receipt of any live vaccine during study participation including up to 120 days after the last dose of study drug. 4. Current enrollment in another investigational study; with the exception of Study M14-197, which is required. 5. Consideration by the Investigator, for any reason, that the subject is an unsuitable candidate to continue to receive ABT-122.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| American College of Rheumatology (ACR) 20 response rate by visit | From Week 0 to Week 24 | ACR criteria measure improvements in tender and swollen joint counts, patient assessments of pain, global disease activity and physical function, physician global assessment of disease activity and acute phase reactant. |
| American College of Rheumatology (ACR) 50 response rate by visit | From Week 0 to Week 24 | ACR criteria measure improvements in tender and swollen joint counts, patient assessments of pain, global disease activity and physical function, physician global assessment of disease activity and acute phase reactant. |
| American College of Rheumatology (ACR) 70 response rate by visit | From Week 0 to Week 24 | ACR criteria measure improvements in tender and swollen joint counts, patient assessments of pain, global disease activity and physical function, physician global assessment of disease activity and acute phase reactant. |
| Change in American College of Rheumatology (ACR) the individual component by visit | From Week 0 to Week 24 | ACR criteria measure improvements in tender and swollen joint counts, patient assessments of pain, global disease activity and physical function, physician global assessment of disease activity and acute phase reactant. |
| Change in Disease Activity Score DAS28 [hsCRP] by visit | From Week 0 to Week 24 | Determine by disease activity score using 28 joint counts (DAS28) and high-sensitivity C-reactive protein (hsCRP) lab test. |
| Change in Psoriatic Disease Activity Score (PASDAS) by visit | From Week 0 to Week 24 | PASDAS determined by tender or swollen joint counts, patient reported outcome and hsCRP lab test. |
| Change in Psoriasis Area and Severity Index (PASI) by visit | From Week 0 to Week 24 | Determined by scores for the amount and severity of a patient's psoriasis. |
| Change in Psoriasis Target Lesion Score by visit | From Week 0 to Week 24 | Determined by plaque erythema, plaque scaling and plaque thickness scores. |
| Change in Dactylitis Assessment by visit | From Week 0 to Week 24 | Determined by presence of dactylitis, swelling, and tenderness in each digit of both hands and both feet. |
| Change in Enthesitis Sites Comprising the Total Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index by visit | From Week 0 to Week 24 | Determined by the presence and severity of enthesitis. |
| Change in Self-Assessment of Psoriasis Symptoms (SAPS) by visit | From Week 0 to Week 24 | Determined by scores given by patients regarding the severity of their psoriatic symptoms. |
| Change in skin biopsy/biomarkers | From Week 0 to Week 24 | Optional samples to assess changes related on disease activity/prognosis of psoriatic arthritis (PsA), autoimmunity/inflammation, and/or response to anti-PsA medications. |
| Change in the quality of life, function and work as measured by the Short-Form Health Survey Version 2.0 (SF36v2) by visit | From Week 0 to Week 24 | Quality of life are self reported measures to assess the physical function of the patient and how their activities are impacted by their disease. |
| Change in the quality of life, function and work as measured by Bath AS Disease Activity Index (BASDAI) by visit | From Week 0 to Week 24 | Quality of life are self reported measures to assess the physical function of the patient and how their activities are impacted by their disease. |
| Change in the quality of life, function and work as measured by the Fatigue Numeric Rating Scale by visit | From Week 0 to Week 24 | Quality of life are self reported measures to assess the physical function of the patient and how their activities are impacted by their disease. |
| Change in the quality of life, function and work as measured by the Sleep Quality Scale by visit | From Week 0 to Week 24 | Quality of life are self reported measures to assess the physical function of the patient and how their activities are impacted by their disease. |
Countries
Australia, Bulgaria, Czechia, Germany, Hungary, Latvia, New Zealand, Poland, Romania, Spain
Outcome results
None listed